Share this article
The United States Patent Trial and Appeal Board (PTAB) has rejected a challenge against Aker BioMarine’s patent US10,010,567B2. According to the company, this patent protects capsules of high-quality krill oil comprising at least 35% phospholipids and low levels of free fatty acids.
Previously, PTAB concluded that the patent has been upheld and validated on all accounts. Further, all procedural options were exhausted, giving Aker a strong patent covering sales of krill oil in the United States until March 2028.
The company has focused on the nutraceuticals market by both developing its own patented technology and by acquiring technology developed by others. The company has one of the world’s largest and most innovative patent portfolios in the krill industry.
Strong Patent Portfolio in the US
In more detail, Kristin Holmgren, intellectual property manager at Aker BioMarine said: “This is further validation of Aker BioMarine’s contribution to the industry’s technology and our innovative capabilities. We will continue to develop our portfolio based on our research and development. To provide our customers with a superior product and are very pleased that PTAB has recognized our efforts.”
Regarding future investments, Simon Seward, EVP of Human Health and Nutrition at Aker BioMarine, noted: “We have invested heavily into our sustainable harvesting method, value chain, and product R&D for the past 16 years. Today, we hold a strong position as an industry leader globally. We are passionate about producing the best krill oil on the market. We will continue to invest in solid partnerships, as this is certainly a great asset for our customers.”
About Aker BioMarine
Aker BioMarine is a biotech innovator and Antarctic krill-harvesting company, dedicated to improving human and planetary health. The company develops krill-based ingredients for pharmaceutical, nutraceutical (Superba®), aquaculture(QRILL®Aqua), and animal feed applications (QRILL®Pet). Including INVI™, a highly concentrated protein isolate, and LYSOVETA™, a targeted transporter of EPA and DHA from krill.
Aker BioMarine’s fully transparent value chain stretches from sustainable krill harvesting in pristine Antarctic waters. Through its Montevideo logistics hub, and Houston production plant to customers around the world. The company’s strong focus on sustainability inspired the launch of AION by Aker BioMarine. A circularity company dedicated to helping companies to recycle and reuse waste.
Share this article